Comparative Pharmacology
Head-to-head clinical analysis: MATULANE versus MEXATE AQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MATULANE versus MEXATE AQ.
MATULANE vs MEXATE-AQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Terminal elimination half-life is approximately 3–10 hours for low doses (<30 mg/m²) and 8–15 hours for high doses (>80 mg/m²). Prolonged to 48–72 hours in patients with third-space effusions or renal impairment.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Renal excretion predominates (80-90% as unchanged drug) via glomerular filtration and active tubular secretion. Biliary/fecal elimination is minor (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent